Skip to content

Study · Case report or series · n = 1 · 2022

3 results

PSUN241 A Case of Dulaglutide-Induced Acute Pancreatitis in a Diabetic Patient – A Case Report

The source lists no authors.

Journal of the Endocrine Society1 Nov 2022

PMCIDPMC9627820 (opens in a new tab)PepBankPUB-98515517
Read at sourceSource pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A man with T2D developed CT-confirmed pancreatitis after dulaglutide dose escalation.

    In plain wordsA man developed pancreatitis after his dulaglutide dose increased.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAcute pancreatitis
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.5 mg weekly increased to 3 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    Computed tomography scan of the abdomen confirmed pancreatitis.
    1 context sentence
    Summary · context
    77-year-old type II diabetic male on Dulaglutide 1.5 mg weekly which was increased to 3 mg weekly 2 weeks prior to a presentation presented with epigastric pain, nausea, and vomiting for 2 days.
  2. 02HumanCase report or seriesSafety outcome

    A man with T2D taking dulaglutide had a lipase value of 953 during pancreatitis.

    In plain wordsA man taking dulaglutide had elevated pancreatic enzymes during pancreatitis.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableLipase elevation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.5 mg weekly increased to 3 mg weeklyAs given in this study (human).

    Measurements

    Lipase
    953 not stated
    during pancreatitis

    Source sentences

    Summary
    Laboratory workup was remarkable for Lipase of 953, otherwise, Calcium, triglycerides, liver enzymes were within normal limit.
    1 context sentence
    Summary · context
    77-year-old type II diabetic male on Dulaglutide 1.5 mg weekly which was increased to 3 mg weekly 2 weeks prior to a presentation presented with epigastric pain, nausea, and vomiting for 2 days.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 03HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome

    In the patient with T2D, symptoms resolved after dulaglutide was held and standard pancreatitis treatment was given.

    In plain wordsThe patient's symptoms resolved after dulaglutide stopped and pancreatitis treatment began.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseSymptom resolution
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Holding Dulaglutide with standard treatment for pancreatitis resulted in symptom resolution.
    1 context sentence
    Summary · context
    77-year-old type II diabetic male on Dulaglutide 1.5 mg weekly which was increased to 3 mg weekly 2 weeks prior to a presentation presented with epigastric pain, nausea, and vomiting for 2 days.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.